Toxicity and Antileishmanial Activity of a New Stable Lipid Suspension of Amphotericin B
AUTOR(ES)
Larabi, Malika
FONTE
American Society for Microbiology
RESUMO
The aim of the present study was to evaluate the toxicity and the activity of a new lipid complex formulation of amphotericin B (AMB) (LC-AMB; dimyristoyl phosphatidylcholine, dimyristoyl phosphatidylglycerol, and AMB) that can be produced by a simple process. Like other lipid formulations, this new complex reduced both the hemolytic activity of AMB (the concentration causing 50% hemolysis of human erythrocytes, >100 μg/ml) and its toxicity toward murine peritoneal macrophages (50% inhibitory concentration, >100 μg/ml at 24 h). The in vivo toxicity of the new formulation (50% lethal dose, >200 mg/kg of body weight for CD1 mice) was similar to those of other commercial lipid formulations of AMB. The complex was the most effective formulation against the DD8 strain of Leishmania donovani. It was unable to reverse the resistance of an AMB-resistant L. donovani strain. In vivo LC-AMB was less efficient than AmBisome against L. donovani.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=296203Documentos Relacionados
- Design and Antileishmanial Activity of Amphotericin B-Loaded Stable Ionic Amphiphile Biovector Formulations
- Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis.
- Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys.
- Unusual lipid structures selectively reduce the toxicity of amphotericin B.
- Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.
